Cancer Drug Prices in India Could Fall by Up to 70% Under New Government Policy

Cancer treatment in India could become more affordable following a government decision to limit trade margins on non-scheduled anti-cancer medicines to 30%. The measure is expected to reduce the maximum retail prices of some cancer drugs by as much as 70% and potentially save patients around ₹2,500 crore annually.

The policy aims to address substantial mark-ups in the medicine supply chain, which can increase the amount patients pay for essential treatment. It extends price-related safeguards to cancer medicines that are not covered by the existing schedule of government-regulated drug prices.

The decision was announced on October 8, 2026, by the central government. Its impact will depend on the medicines covered, their existing prices and the margins currently applied by distributors and retailers.

How the 30% Trade Margin Cap Will Work

A trade margin is the difference between the price at which a medicine enters the distribution chain and the amount charged to the customer. When these margins are high, the final retail price can be considerably greater than the initial selling price.

Under the new approach, trade margins on non-scheduled anti-cancer medicines will be restricted to 30% of the maximum retail price (MRP). The government expects this change to bring down prices for medicines that currently carry substantial mark-ups.

The measure is intended to cover branded and generic medicines, including products manufactured in India and those imported from overseas. Both patented and non-patented medicines are included within the stated scope, subject to the applicable policy framework.

However, a reduction of 70% should not be expected for every cancer drug. The government’s estimate represents the potential maximum reduction, while the actual change will vary according to the existing pricing structure of individual medicines.

Which Cancer Medicines Will Be Affected?

The policy focuses on non-scheduled anti-cancer medicines, which fall outside the existing list of drugs subject to specific government ceiling prices. Essential cancer medicines already included in the scheduled category are regulated through a separate price-control mechanism.

An expert committee under the Directorate General of Health Services is responsible for finalising the list of medicines to be covered by the expanded intervention. The precise impact on individual treatments will therefore depend on the final list and implementation of the rules.

The move follows concerns about large differences between the prices at which some cancer medicines are supplied to retailers and the MRPs patients are asked to pay. Such gaps can add substantially to treatment expenses, particularly when medicines must be purchased repeatedly over an extended period.

How Much Could Patients Save?

The government estimates that the expanded price-control measure could generate annual savings of approximately ₹2,500 crore for cancer patients across India.

For families paying for treatment themselves, lower medicine prices could ease some of the financial pressure associated with cancer care. Drug expenses can form a significant part of treatment costs, alongside hospital stays, diagnostic tests, consultations and other medical services.

The extent of individual savings will depend on the medicines prescribed and how much their prices change. Patients should not assume that the entire cost of cancer treatment will fall by the same percentage, because the policy targets medicine pricing rather than every component of healthcare expenditure.

Previous Price-Control Measures Provide a Precedent

India has previously used trade margin rationalisation to address the cost of cancer medicines. In 2019, a similar intervention covered 42 non-scheduled anti-cancer medicines.

That earlier initiative provides a precedent for using limits on distribution margins to reduce retail prices without setting an entirely separate ceiling price for every formulation and brand.

The latest measure expands the approach to a wider range of cancer medicines, including expensive treatments that may otherwise remain outside the scheduled price-control framework.

What the Decision Means for Cancer Care

The new policy could improve access to selected cancer medicines by reducing the amount patients pay at pharmacies and other authorised supply points. Its success will depend on effective implementation, transparent pricing and continued availability of the medicines concerned.

Lower retail prices would be an important step towards reducing the financial burden of cancer treatment, but affordability also depends on diagnosis costs, hospital charges and access to appropriate care.

For patients and families, the key development is the government’s attempt to curb excessive trade margins. Once the final list and revised prices are implemented, the actual reductions will become clearer, offering a better picture of how much the policy changes the cost of cancer medicines in India.